natgillin/translations-raw huggingface dataset:
Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.
Učinak klase - Simptomi distonije, produžene abnormalne kontrakcije mišićnih skupina, mogu nastati u podložnih pojedinaca tijekom prvih nekoliko dana liječenja.
Class effects
Učinak skupine lijeka
Class effects
Učinci skupine lijeka
Class effects
Učinci skupine lijekova
Class effects for granisetron seen with other formulations (oral and intravenous) include the following:
Učinci skupine za granisetron uočeni kod drugih oblika primjene (peroralnog i intravenskog) uključuju:
Class effects:
Učinci skupine:
Class I collagenases (α, β, γ, and η) are the products of the colG gene, they initiate collagen hydrolysis near the amino and carboxy termini of triple helical domains, and generate large proteolytic fragments.
Kolagenaze skupine I (α, β, γ i η) proizvodi su gena colG, započinju hidrolizu kolagena u blizini amino- i karboksi-kraja domena trostrukog heliksa i stvaraju velike proteolitičke fragmente.
Class Ia and class III antiarrhythmic medicinal products have been associated with cases of torsades de pointes in patients with bradycardia.
Antiaritmici klase Ia i klase III bili su povezani sa slučajevima aritmije torsades de pointes u bolesnika s bradikardijom.
Class related adverse reactions
Nuspojave povezane s ovom skupinom lijekova
Classical biotransformation studies have not been conducted.
Klasične studije biotransformacije nisu provedene.
Classical biotransformation studies have not been performed.
Klasična ispitivanja biotransformacije nisu bila provođena.
CLASSIFICATION FOR SUPPLY
NAČIN IZDAVANJA LIJEKA
CLASSIFICATION FOR SUPPLY
NAČIN PROPISIVANJA LIJEKA
CLcr (ml/min) = -------------------------------------- (x 0.85 for women)
CLcr (ml/min) = --------------------------------------------- (x 0,85 za žene)
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women)
CLcr (ml/min) = ----------------------------------------- (x 0,85 za žene)
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women)
CLcr (ml/min) = --------------------------------------------- (x 0,85 za žene)
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women)
CLcr (ml/min) = ---------------------------------------------- (x 0,85 za žene)
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women)
CLcr (ml/min) = ----------------------------------------------- (x 0,85 za žene)
CLcr (ml/min)= ----------------------------------------- (x 0.85 for women)
CLcr (ml/min) = --------------------------------------------- (x 0,85 za žene)
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73
CLcr (ml/min/1,73 m2) = ------------------------------ x 1,73
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73
CLcr (ml/min/1,73 m2) = ------------------------------- x 1,73
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73
CLcr (ml/min/1,73 m2) = --------------------------------- x 1,73
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73
CLcr (ml/min/1.73 m2) = ------------------------------ x 1,73
CLcr (ml/min/1.73 m2) = -------------------------------- x 1.73
CLcr (ml/min/1,73 m2) = --------------------------- x 1,73
CLCR 30-60 ml/min: initial dose of 200 mg once daily or 400 mg every other day for 2 weeks followed by a once daily dose of 400 mg.
CLCR 30-60 ml/min: početna doza od 200 mg jedanput dnevno ili 400 mg svaki drugi dan kroz 2 tjedna, nakon toga jedanput dnevno doza od 400 mg.
CLCR <30 ml/min: use is not recommended in patients with severe renal impairment due to insufficient data.
CLCR <30 ml/min: ne preporučuje se koristiti u bolesnika s teškim oštećenjem bubrega zbog nedostatnih podataka.
CLCR >60 ml/min: no dose adjustment required.
CLCR >60 ml/min: nije potrebna prilagodba doze
CLCR >60 ml/min: no dose adjustment required.
CLCR >60 ml/min: nije potrebna prilagodba doze.
CLDT600A2303 - Off-treatment durability of HBeAg responses
CLDT600A2303 – Trajanje odgovora na HBeAg u periodu bez liječenja
Clean about 5 cm around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding.
Očistite približno 5 cm oko točke u koju ćete ubosti iglu i ostavite dezinfekcijsko sredstvo da se osuši najmanje jednu minutu prije nego što nastavite s postupkom.
Clean and disinfect the skin where the injection is to be made with a cleansing swab.
Vatom za čišćenje očistite i dezinficirajte mjesto na koži u koje ćete ubrizgati injekciju.
Clean and dry the areas of the skin where you will be using the cream.
Očistite i osušite područja kože na kojima ćete koristiti kremu.
Clean each of the rubber stoppers with antiseptic solution and allow them to dry.
Svaki gumeni čep očistite antiseptičkom otopinom i pustite ih da se osuše.
Clean hands before handling the cow's udder.
Operite ruke prije diranja vimena.
Clean skin in the injection area with an alcohol wipe.
Očistite kožu na mjestu injiciranja tupferom natopljenim alkoholom.
Clean the cartridge rubber seal with an alcohol swab or cotton ball saturated with alcohol.
Očistite gumeni čep uloška alkoholnom ili pamučnom vaticom natopljenom alkoholom.
Clean the chosen injection site with one of the provided alcohol swabs.
Očistite željeno mjesto ubrizgavanja jednom od isporučenih kompresa natopljenih alkoholom.
Clean the chosen skin area with an alcohol swab using a circular motion.
Obrišite odabrano mjesto kružnim pokretima vatom natopljenom alkoholom.
Clean the chosen skin area with an alcohol swab using a circular motion.
Očistite odabrano područje kože kružnim pokretima vatom natopljenom alkoholom.
Clean the ears before the initial treatment is applied.
Očistite uši prije primjene početne terapije.
Clean the flat work surface with a new alcohol swab.
Očistite ravnu radnu površinu novom vaticom natopljenom alkoholom.
Clean the injection area with the alcohol swab as instructed by your healthcare provider.
Očistite područje injiciranja alkoholom natopljenom vaticom prema uputama svog liječnika.
Clean the injection site with a new alcohol swab.
Očistite mjesto primjene novim tupferom natopljenim alkoholom.
Clean the injection site with a rubbing alcohol pad and allow it to dry.
Očistite mjesto uboda injekcije blazinicom natopljenom alkoholom i pustite da se osuši.
Clean the injection site with an alcohol swab and let it dry.
Očistite ubodno mjesto jastučićem natopljenim alkoholom i pustite da se osuši.
Clean the injection site with an alcohol wipe and let it air-dry.
Očistite mjesto injiciranja s tupferom natopljenim alkoholom i pustite da se osuši.
Clean the injection site with the alcohol swab.
Očistite odabrano područje kože kružnim pokretima vatom natopljenom alkoholom.
Clean the injection site.
Očistite mjesto injiciranja.
Clean the intended site of injection on your skin with an alcohol swab, using a circular motion, working outwards.
Mjesto na koži koje ste odabrali za davanje injekcije očistite alkoholnom maramicom, kružnim pokretima prema van.
Clean the lesion and surrounding areas with an alcohol swab and let dry.
Očistite leziju i okolna područja alkoholnom maramicom i pustite da se osuši.
Clean the mixing equipment.
Očistite opremu za miješanje.
Clean the oral syringe immediately with water.
Štrcaljku za usta treba odmah oprati vodom.
Clean the pen with a cloth moistened with a mild detergent.
Čistite brizgalicu tkaninom navlaženom blagim deterdžentom.
Clean the rubber stopper of the vial containing the Ilaris solution with a new alcohol swab.
Očistite gumeni čep bočice koja sadrži otopinu Ilarisa novim tupferom natopljenim alkoholom.
Clean the rubber stopper on the top of the vial containing the IntronA solution with a cleansing swab.
Očistite gumeni čep na vrhu bočice IntronA otopinom tupferom za čišćenje.
Clean the rubber stopper on the top of the vial containing the IntronA solution with a cleansing swab.
Tupferom za čišćenje očistite gumeni čep na vrhu bočice koja sadrži IntronA otopinu.
Clean the rubber top of the vial with a cleansing swab.
Očistite gumeni vrh bočice tupferom za čišćenje.
Clean the rubber top of the vial with a cleansing swab.
Očistite gumeni vrh bočice vatom za čišćenje.
Clean the skin at the injection site by wiping it with an alcohol swab
Očistite kožu na mjestu injekcije blazinicom natopljenom alkoholom.
Clean the skin at the injection site using an alcohol wipe.
Kožu na mjestu injiciranja očistite vaticom natopljenom alkoholom.
Clean the skin at your chosen injection site with your second alcohol swab - use a circular motion.
Kružnim pokretima očistite kožu na izabranom mjestu injekcije drugom blazinicom natopljenom alkoholom.
Clean the skin where you are going to give yourself the injection with a fresh cleansing swab.
Očistite kožu na mjestu gdje ćete si dati injekciju novim tupferom za čišćenje.
Clean the stopper with an antiseptic swab
Očistite čep antiseptičkom maramicom.
Clean the stoppers with the alcohol swab.
Očistite čepove tupferom natopljenim alkoholom.
Clean the Turbospin inhaler after each dose using the following procedure:
Inhalator Turbospin očistite nakon svake doze na sljedeći način:
Clean the vial stopper with a fresh alcohol wipe, and leave it to dry completely.
Očistite čep bočice novom vaticom natopljenom alkoholom i ostavite ga da se osuši do kraja.
Clean your hands
Operite ruke
Clean your injection site with an alcohol wipe.
Očistite područje injiciranja alkoholnom maramicom.
Clean your injection site.
Očistite područje injiciranja.
clean, dry cotton swabs
čisti, suhi pamučni tupferi
Clean, Empty Cup
Čista, prazna čaša Sat/mjerač vremena
Clean, Empty Cup ------------------------- Clock/Timer
Čista, prazna čaša Sat/mjerač vremena
Cleaning the cup and syringe
Čišćenje čaše i štrcaljke
Cleaning the nasal spray After each use:
Čišćenje spreja za nos Nakon svake uporabe:
Cleaning the Turbospin device
Čišćenje inhalatora Turbospin
Cleaning up
Čišćenje
Cleaning your Inhaler
Čišćenje inhalatora
Cleanse surgical instruments, gloves and adjacent tissues, if necessary.
Očistite kirurške instrumente, rukavice i okolna tkiva, ako je potrebno.
Clear (PCTFE/PVC/Aluminium) blister of 10 or 14 (calendar blister) tablets.
Prozirni (PCTFE/PVC/Aluminij) blister s 10 ili 14 (kalendarski blister) tableta.
Clear / almost clear Marked improvement Improved
Čista/gotovo čista koža Znatno poboljšanje Poboljšano
Clear and colourless solution for injection.
Bistra i bezbojna otopina za injekciju.
Clear and colourless solution.
Bistra i bezbojna tekućina.
Clear and colourless solutions without visible particles should be used.
Smiju se koristiti samo bistre i bezbojne otopine bez vidljivih čestica.
Clear any liquid from the thinnest section of the tube by flicking just below the membrane.
Uklonite svu tekućinu s najtanjeg dijela tube kuckanjem neposredno ispod membrane.
Clear Cartridge
Prozirni uložak
Clear colourless capsules containing a white to almost white powder, with “NVR AVCI” printed in blue on one part of the capsule and Novartis logo printed in blue on the other part of the capsule.
Prozirne bezbojne kapsule koje sadrže bijeli do gotovo bijeli prašak, s oznakom „NVR AVCI“ otisnutom plavom bojom na jednom dijelu kapsule i logotipom Novartisa otisnutim plavom bojom na drugom dijelu kapsule.
Clear colourless hard capsules marked with ‘PXS 40 mg’ and containing white or almost white powder.
Prozirne, bezbojne tvrde kapsule s oznakom ‘PXS 40 mg’ koje sadrže bijeli ili gotovo bijeli prašak.
Clear colourless liquid
Bistra, bezbojna tekućina.
Clear colourless to slightly yellow solution for injection.
Bistra bezbojna do žućkasta otopina za injekciju.
Clear colourless to slightly yellow solution for injection.
Bistra bezbojna do žućkasta tekućina.
Clear colourless to slightly yellow solution.
Bezbojna do žućkasta otopina.
Clear colourless Type I 20 ml glass vial sealed with a butyl rubber stopper and an aluminium seal with plastic flip-off cap containing 50 mg decitabine.
Bočica od 20 ml od prozirnog bezbojnog stakla tipa I, zatvorena butilnim gumenim čepom i aluminijskim prstenom s plastičnom „flip-off“ kapicom; bočica sadrži 50 mg decitabina.
Clear dark blue solution with a pH value between 3.0 and 4.5 Osmolality is usually between 10 and 15 mOsm/kg.
Bistra, tamnoplava otopina pH vrijednosti između 3,0 i 4,5 Osmolalnost je obično između 10 i 15 mOsm/kg.
Clear glass (type I) syringe with stainless steel needle, rubber needle cover and plastic plunger containing 0.98 ml of solution.
Štrcaljka od prozirnog stakla (tipa I) s iglom od nehrđajućeg čelika, gumenim poklopcem za iglu i plastičnim klipom koja sadrži 0,98 ml otopine.
Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and a red flip-off cap, containing 4 ml of concentrate.
Prozirna staklena bočica (staklo tip I) s fluorotec plus gumenim čepom, aluminijskim prstenom i crvenim plastičnim "flip-off" zatvaračem, koja sadrži 4 ml koncentrata.
Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and a red flip-off cap, containing 8 ml of concentrate.
Prozirna staklena bočica (staklo tip I), s fluorotec plus gumenim čepom (etilen-tetrafloretilen), aluminijskim zatvaračem i crvenom „flip-off „ zaštitnom kapicom, s 8 ml koncentrata.
Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and an orange flip-off cap, containing 1 ml of concentrate.
Prozirna staklena bočica (staklo tip I), sa zelenim aluminijskim zatvaračem i narančastom „flip-off „ zaštitnom kapicom, koja sadrži 1 ml koncentrata
Clear glass (Type I) vials with a bromobutyl rubber stopper, sealed with an aluminium cap.
Bočice od prozirnoga stakla (tip I), s čepom od bromobutilne gume, dodatno učvršćenim aluminijskom zatvaračem.
Clear glass syringe (type I glass) with stainless steel needle, rubber needle cover and plastic plunger.
Štrcaljka od prozirnog stakla (staklo tipa I) s iglom od nehrđajućeg čelika, gumenim poklopcem za iglu i plastičnim klipom.
Clear glass vial (4 ml, type I glass) with rubber stopper, aluminium seal, and flip-off plastic cap.
Bočica od prozirnog stakla (4 ml, staklo tipa I) s gumenim čepom, aluminijskim prstenom i plastičnom kapicom.
Clear glass vial (type 1 glass) with butyl rubber stopper and a plastic flip-top closure sealed with aluminum containing 1.2 ml of concentrate
Bočica od prozirnog stakla (staklo tipa 1) s čepom od butilne gume i plastičnim poklopcem i aluminijskim prstenom koja sadrži 1,2 ml koncentrata.
Clear glass vial (type 1 glass) with butyl rubber stopper and a plastic flip-top closure sealed with aluminum containing 2.2 ml of diluent
Bočica od prozirnog stakla (staklo tipa 1) s čepom od butilne gume i plastičnim poklopcem i aluminijskim prstenom koja sadrži 2,2 ml otapala
Clear Liquid in Syringe
Bistra tekućina u štrcaljki
Clear opalescent suspension for injection
Bistra opalescentna suspenzija za injekciju
Clear opalescent suspension.
Bistra opalescentna suspenzija.
clear or almost clear
bez promjena ili gotovo bez promjena
Clear pale yellow liquid. pH = 2.0-2.6.
Bistra blijedo žuta tekućina. pH = 2,0 – 2,6.
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Prozirni PCTFE/PE/PVC blister zapečaćen aluminijskom folijom, koji sadrži 3 ili 6 tableta za žvakanje u kartonskoj kutiji.
Clear polyvinyl chloride (PVC)/polyethylene (PE)/polychlorotrifluoroethylene (Aclar) aluminium blister packages of 30 and 100 tablets.
30 ili 100 tableta u prozirnim polivinilklorid (PVC)/polietilen (PE)/ poliklorotrifluoroetilen (Aclar) aluminijskim blister pakiranjima.
Clear PVC/CTFE/aluminium or PVC/PVDC/aluminium blisters in cartons containing 7, 14, 28, 49, 56 or 98 tablets as unit pack or in multipacks containing 140 (10x14) tablets.
Prozirni PVC/CTFE/ aluminij ili PVC/PVDC/ aluminij blisteri u kutijama koje sadrže 7, 14, 28, 49, 56 ili 98 tableta kao pojedinačno pakovanje ili višestruka pakovanja koja sadrže 140 (10x14) tableta.
Clear solution, colourless to pale-yellow, essentially free from visible particulates.
Bistra, bezbojna do blijedo-žuta otopina, uglavnom bez vidljivih čestica.
Clear to semi-translucent liquid following thaw from its frozen state.
Prozirna do poluprozirna tekućina nakon otapanja iz zamrznutog stanja.
Clear to slightly opalescent, colourless to slightly yellow solution, pH 5.2 – 5.8.
Bistra do blago opalescentna, bezbojna do blijedo žuta otopina (pH 5,2 – 5,8).
Clear to slightly opalescent.
Prozirna do blago opalescentna.
Clear type 1, 5 ml VIAL
Prozirna tip 1, BOČICA od 5 ml
Clear type I glass 2 ml vial with a chlorobutyl/butyl rubber stopper and aluminium seal with a plastic flip-off cap.
Bočica od prozirnog stakla tipa I, volumena 2 ml, s klorbutilnim/butilnim gumenim čepom i aluminijskim zaštitnim zatvaračem s plastičnom „flip-off“ kapicom.
Clear Type I glass vial with a bromobutyl rubber stopper and aluminium flip-off seal containing 5 mL of concentrate for solution for infusion.
Bočica od prozirnog stakla tipa I s čepom od bromobutilne gume i aluminijskim flip-off zatvaračem, koja sadrži 5 mL koncentrata za otopinu za infuziju.
Clear Type I glass vial with a latex-free bromobutyl rubber stopper and aluminium over-seal, containing 5 ml of concentrate for solution for infusion.
Prozirna staklena bočica (tip I) s gumenim čepom od brombutilne gume bez lateksa te aluminijskim prstenom, koja sadrži 5 ml koncentrata za otopinu za infuziju.
Clear Type I glass vial with a latex-free bromobutyl rubber stopper and aluminium over-seal, containing 50 ml of concentrate for solution for infusion.
Prozirna staklena bočica (tip I) s gumenim čepom od brombutilne gume bez lateksa te aluminijskim prstenom, koja sadrži 50 ml koncentrata za otopinu za infuziju.
Clear type I glass vials closed by a grey butyl or black chlorobutyl rubber stopper covered with a crimped-on aluminium ring and a cap.
Bočice od prozirnog stakla tipa I zatvorene sivim gumenim čepom od butila ili crnim gumenim čepom od klorobutila i prekrivene aluminijskim prstenom i zatvaračem.
Clear yellow solution. pH: 8.1-8.5; osmolality: 270-330 mOsmol/kg
Bistra žuta otopina. pH: 8,1-8,5; osmolalnost: 270-330 mOsmol/kg
Clear yellow to brownish solution.
Bistra žuta do smećkasta otopina.
Clear yellowish solution.
Bistra žućkasta tekućina.
Clear, colorless 10 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip- off cap, containing 100 mg of pemetrexed.
Prozirna, bezbojna bočica (staklo tipa I) od 10 ml s klorbutilnim gumenim čepom i aluminijskim zatvaračem i flip-off kapicom, koja sadrži 100 mg pemetrekseda.
Clear, colorless 100 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip-off cap, containing 1000 mg of pemetrexed.
Prozirna, bezbojna bočica (staklo tipa I) od 100 ml s klorbutilnim gumenim čepom i aluminijskim zatvaračem i flip-off kapicom, koja sadrži 100 mg pemetrekseda.
Clear, colorless 50 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip- off cap, containing 500 mg of pemetrexed.
Prozirna, bezbojna bočica (staklo tipa I) od 100 ml s klorbutilnim gumenim čepom i aluminijskim zatvaračem i flip-off kapicom, koja sadrži 100 mg pemetrekseda.
Clear, colourless or almost colourless, isotonic solution; pH=8.15.
Bistra, bezbojna ili gotovo bezbojna, izotonična otopina; pH=8,15.
Clear, colourless solution without particles.
Prozirna, bezbojna otopina, bez čestica.
Clear, colourless solution.
Bistra bezbojna otopina.
Clear, colourless solution.
Bistra, bezbojnaotopina.
Clear, colourless solution.
Otopina je bistra i bezbojna.
Clear, colourless to light yellow liquid solution.
Bistra, bezbojna do svijetložuta tekućina.
Clear, colourless to pale yellow in colour.
Bistra, bezbojna do blijedo žute boje.
Clear, colourless to pale yellow solution
Bistra, bezbojna do blijedo žuta otopina
Clear, colourless to pale yellow solution
Bistra, bezbojna do blijedožuta otopina
Clear, colourless to pale yellow solution. pH: 6.0 – 7.5
Bistra, bezbojna do blijedožuta otopina. pH: 6,0 – 7,5
Clear, colourless to slightly coloured (pink) liquid.
Bistra, bezbojna do blago obojena (ružičasta) tekućina.
Clear, colourless to slightly yellow, solution with a pH: 6.3 ±0.3.
Bistra, bezbojna do blago žućkasta otopina sa pH: 6,3 ±0,3.
Clear, colourless to yellowish solution.
Bistra bezbojna do žućkasta otopina.
Clear, colourless, aqueous solution.
Bistra, bezbojna, vodena otopina
Clear, colourless-to-white solution for injection that may contain some product-related translucent-to- white amorphous particles.
Bistra, bezbojna do bijela otopina za injekciju koja može sadržavati neke prozirne do bijele amorfne čestice porijeklom od lijeka.
Clear, Type I, flint glass, single-use vial, grey butyl rubber stopper, and aluminium overseal with flip- off-cap.
Prozirno silikatno staklo tipa I, bočica za jednokratnu primjenu, sivi čep od butil gume i aluminijski prsten s „flip-off“ kapicom.
Clear, Type III glass, bottle with a high density polyethylene (HDPE) child-resistant closure.
Boca od prozirnog stakla tipa III sa sigurnosnim zatvaračem za djecu od polietilena visoke gustoće (HDPE).
Clear, yellow solution.
Bistra žuta otopina.
CLEAR1 and CLEAR2 enrolled patients with gout who were on a stable dose of allopurinol of at least 300 mg (or 200 mg for moderate renal impairment), had serum uric acid levels greater than 6.5 mg/dL and reported at least 2 gout flares in the previous 12 months.
U ispitivanja CLEAR1 i CLEAR2 uključeni su bolesnici s gihtom koji su liječeni stabilnom dozom alopurinola od najmanje 300 mg (ili 200 mg u slučaju umjerenog oštećenja funkcije bubrega), koji su imali razine mokraćne kiseline u serumu iznad 6,5 mg/dl i u kojih su prijavljena najmanje 2 akutna napadaja gihta u prethodnih 12 mjeseci.
Clearance (dL/(kg.hr))
Klirens (dl/(kg.h))
Clearance (mL/h/kg)
Klirens (ml/h/kg)
Clearance (ml/kg*h)
Klirens
Clearance (ml/kg*h)
Klirens (ml/kg*h)
Clearance and mean terminal half-life t½ of somatropin in adult and paediatric growth hormone deficient patients are similar to those observed in healthy subjects.
Klirens i prosječni poluvijek t½ somatropina kod pedijatrijskih i odraslih bolesnika s nedostatkom hormona rasta slični su onima uočenim kod zdravih ispitanika.
Clearance and volume estimates in patients aged 65 to 87 years were similar to estimates in patients less than 65 years of age.
Procjene klirensa i volumena u bolesnika starosti 65 do 87 godina bile su slične procjenama u bolesnika mlađih od 65 godina
Clearance and volume of distribution were related to body weight by an allometric model with exponents of 0.433 and 1, respectively: as body weight increased from 10 to 60 kg, apparent oral clearance increased from 2.60 to 5.65 L/hr and apparent volume of distribution increased from 32.0 to 191.8 L. As a result, elimination half-life increased from 8.5hr (for 10 kg) to 23.5 hr (for 60 kg).
Klirens i volumen distribucije su bili u odnosu s tjelesnom težinom, prikazano alometrijskim modelom s eksponentom 0,433 i 1: kako se tjelesna težina povećavala od 10 do 60 kg, prividni oralni klirens se povećavao od 2,60 to 5,65 L/h, a prividni volumen distribucije se povećavao od 32,0 to 191,8 L. Posljedično tomu, poluvrijeme eliminacije se povećalo od 8,5h (za 10 kg) do 23,5 h (za 60 kg).
Clearance following subcutaneous dosing was estimated to be 21.0 ml/h in a rheumatoid arthritis population pharmacokinetic analysis, with an inter-subject variability of 30.8% (CV) and an inter- occasion variability of 22.0%.
U farmakokinetičkoj analizi populacije s reumatoidnim artritisom klirens nakon subkutane primjene procijenjen je na 21,0 ml/h, uz varijabilnost između ispitanika od 30,8% (CV) te 22% varijabilnosti između ispitivanja.
Clearance is about 0.1 l/h/kg, and terminal half-life (t1/2) about 1 h.
Klirens je oko 0,1 l/h/kg, a poluvijek (t1/2) oko 1 sat.
Clearance is decreased after repeated administration of stiripentol, probably due to inhibition of the cytochrome P450 isoenzymes responsible for its metabolism.
Klirens se smanjuje poslije ponovljene primjene stiripentola, vjerojatno zbog inhibicije citokrom P450 izoenzima odgovornih za njegov metabolizam.